Project/Area Number |
24592245
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Orthopaedic surgery
|
Research Institution | Tokyo Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
YAMAMOTO Kengo 東京医科大学, 医学部, 教授 (10246316)
SAWAJI Yasunobu 東京医科大学, 医学部, 助教 (20571152)
|
Co-Investigator(Renkei-kenkyūsha) |
KURODA Masahiko 東京医科大学, 医学部, 教授 (80251304)
|
Project Period (FY) |
2012-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | (1) PLFs / miR-543 / miR-155-5p / miR132-3p / EP4 agonist / MH7A / 非感染性人工関節弛緩(APL) / PLFs / miRNA155 / TWIST1 / POSTN / MMP1 / MH7a / RAFs / miR-155 / TWIST / 人工関節弛緩 / miRNA array / real time-PCR / APL / miRNA |
Outline of Final Research Achievements |
This study was to investigate miRNA expression profiling stimulated with EP4 agonist in PLFs and to evaluate the function of miR-155 in PLFs and MH7A . Agilent miRNA Array systems was used to screen for differentially expressed miRNAs in PLFs. Enforced over expression of miR-155 were used to investigate the function of miR-155 in PLFs and MH7A. Expression of Twist1, POSTN and MMP1 which were previously identified as the actual target of activity of PLFs and MH7A were examined by Western blot and real-time PCR . As a result of miRNA array system, the expression of miR-543 and miR-132-3p were significantly increased in EP4 agonist treated PLFs compared with non-treatedPLFs. The expression of miR-155-5p was decreased in EP4 agonist and IL-1b treated PLFs compared with IL-1btreated PLFs. Upregulation of miR-155 suppressed Twist1, POSTN, and MMP-1 levels. There is a possibility that these miRNA are an alternative treatment of EP4 agonist has been suggested.
|